Metformin and longevity: a careful look at the TAME hypothesis

Metformin is a prescription-only medicine licensed in the UK for type 2 diabetes. It's cheap (around £2/month off-patent), safe in the indicated population, and has been on the WHO Essential Medicines List for decades. It has become a focus of longevity research because of a series of observational findings and the long-running TAME trial proposal.

What sparked the longevity discussion#

A 2014 Diabetes, Obesity and Metabolism study (Bannister et al.) compared survival among type 2 diabetics taking metformin to non-diabetic matched controls. The diabetic group on metformin had slightly better survival than the non-diabetic controls, an unexpected finding, given that diabetes is a strong mortality risk factor.

The interpretation: metformin might have effects beyond glucose control that confer survival benefits.

Subsequent observational data have shown associations between metformin use and reduced incidence of:

• Cancer (modest, mixed across cancer types)
• Cardiovascular events (consistent with diabetes-control benefits)
• Cognitive decline (mixed)
• Frailty markers

The TAME trial#

The Targeting Aging with Metformin (TAME) trial, championed by Nir Barzilai and others, is a proposed multi-site RCT in older non-diabetic adults. The primary endpoint is a composite of major age-related disease (heart attack, stroke, cancer, dementia, mortality) rather than any one outcome.

TAME is significant for the discussion partly because of what it would prove if positive: that a drug can target ageing as a target, with a composite morbidity endpoint, in a regulatory framework. As of the most recent reviews, the trial has faced funding and design challenges; results are not expected soon.

The exercise problem#

Several trials in non-diabetic adults have produced an uncomfortable finding: metformin may blunt some adaptations to exercise. The MASTERS trial (Konopka et al. 2019) reported that metformin reduced the gains in cardiorespiratory fitness from a structured exercise programme in older adults.

The mechanism may be related to mTOR effects or mitochondrial signalling. If true, this matters because exercise is one of the better-evidenced lifespan-extending interventions, and any drug that attenuates its effects has to be weighed against that.

Side effects and tolerability#

Metformin is generally well-tolerated. Common issues:

• GI symptoms (nausea, diarrhoea, abdominal discomfort), usually transient, more common with immediate-release formulations
• Vitamin B12 deficiency with long-term use
• Rare lactic acidosis, mostly in people with significant renal impairment

The safety profile in diabetics over many years is robust. Long-term safety in healthy non-diabetics taking metformin for longevity purposes is less well-studied because the use case is non-licensed.

UK regulatory reality#

Metformin is a POM. Licensed indications are type 2 diabetes and certain related conditions. It is not licensed for "longevity" or "ageing" in the UK. Some private clinics will prescribe off-label for longevity; this requires a prescriber willing to do so with informed consent.

Importing metformin from grey-market sources for personal use is outside UK medicines law and the quality issues with online pharmaceutical sources apply.

Why we won't give dosing#

The therapeutic doses for diabetes are well-known (typically 500–2,000 mg/day in divided doses). The doses used in longevity-oriented off-label prescription vary and are not established. Dose, formulation (immediate vs extended release), and monitoring are clinical decisions.

The honest read#

Metformin sits in a similar category to rapamycin: real biology, intriguing observational signals, no clean human longevity trial yet, prescription-only in the UK. The data for "should a healthy non-diabetic take this" are far weaker than people enthusiastic about the observational findings often imply, and the exercise-blunting signal in MASTERS is a real concern that hasn't been resolved.

Anyone considering off-label use should talk to a UK clinician who specialises in this space, weigh it against the exercise data, and treat the decision as experimental rather than established.

The cheap, well-evidenced longevity intervention metformin gets compared to is (still) exercise.